Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 January, 2022 16:59 IST
Ipca Laboratories board approves acquisition of 26% stake in Lyka Labs
Source: IRIS | 24 Nov, 2021, 05.09PM
Rating: NAN / 5 stars.
Comments  |  Post Comment


Ipca Laboratories, a Mumbai-based drug-maker, announced that the board has approved acquisition of 26.574% of the paid-up share capital of Lyka Labs and has entered into a Joint Management Control Agreement with the Promoters of Lyka Labs. The cost of acquisition is Rs 978.9 million.

Consequent to this acquisition of shares, the Company has also made a public announcement to acquire 26% additional equity shares of the said company from its public shareholders under the SEBI (SAST) Regulations, 2011.

Shares of the company gained Rs 24.55, or 1.19%, to settle  at  Rs 2,082.25  The total volume of shares traded  was 14,650 at  the BSE (Wednesday).




 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
ICICI Bank: Leadership position to strengthen; Tech capabilities to drive sustainable growth - 18-Jan-2022 14:36
UltraTech Cement Q3FY22 Review - Outlook positive; Hold - 18-Jan-2022 14:23
VA Tech Wabag secures order worth USD 100 mn in Dubai - 17-Jan-2022 19:43
Glenmark Pharmaceuticals arm gets tentative approval for Regadenoson Injection - 17-Jan-2022 19:16
HDFC Bank Q3FY22 Review-Credit growth improved; Restructured assets at 1.37% vs 1.5% - 17-Jan-2022 17:25
HCL Technologies Q3FY22 Review- Margins to improve gradually - 17-Jan-2022 17:15
HDFC Bank: Earnings in line; Balance Sheet strengthens further - 17-Jan-2022 16:52
Renaissance Global partners with National Football League - 17-Jan-2022 11:26
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer